Tweets
So time for ORAL Surveillance, malignancy and VTE risk.
I'll go through some of the key points in this thread
#ACR21 ABST1940, ABST1941 @RheumNow https://t.co/pbjM2sFAXz
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
#ACR21 Ab#1940. ORAL Surveillance - Malignancy
▶️Remember: pts had ⬆️ CVD risks incl older, smoker, etc so higher risk group for cancer
⭐️Lung cancer most common
⭐️# to harm ~ 300
⭐️Older age, current/past smoking were independent risk factors
https://t.co/JOKNyYVZfX @RheumNow https://t.co/WeX5uZAubd
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
ORAL Surveillance VTE risk. Significant increase in VTE/PE only at 10mg bd dose. Abstr#1941 #ACR21 @RheumNow https://t.co/WW71syiINE
Richard Conway @RichardPAConway ( View Tweet )
4 years 8 months ago
Sick Leave in axSpA: Who takes more?
Dr. Rachel Tate ( @uptoTate) reviews abstract 0380 presented at #ACR21.
https://t.co/e8cU9rIVB1 https://t.co/ImSjjLK15m
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
@drhalafadhil @ACRheum @nighat @DrDavidKarp (ACR President) who can we contact at ACR who can help mentor her? I believe there is session #GlobalRheumatologySummit that addresses this. @rheumnow #ACR21 #RheumatologyforAll
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 8 months ago
Nature or nurture or both? Genesis #scleroderma US cohort showed Hispanic pts had more RNP, more #SLE overlap & younger but ⬆️mortality vs whites but less mortality vs blacks. Health disparities? Abst#1839 #ACR21 @RheumNow https://t.co/pgYJEXP1fN
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
#ACR21 #Abstr1913 What do our patients think about #Telemedicine?GRA Registry (N=596; 50% RA and #lupus):
💠Most found => effective than In-Person
💠25% dissatisfied and not keen to continue post-COVID
💠Poor predictors: Age, 🇬🇧🇨🇦🇦🇺🇳🇿, Graduates @RheumNow
https://t.co/55UmppwF9P https://t.co/9AyYB4hI3V
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 8 months ago
Guselkumab in Psoriatic Arthritis
Dr. Pedro Castillo ( @_Castillo_Pedro) discuss three abstracts presented at #ACR21 that expand on the use of guselkumab for use with psoriatic arthritis.
https://t.co/hAbLTU4epW https://t.co/p33p6iysjX
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
It was real...
no sugar coating...
the pandemic was tough...
But no match for these women!
You can watch on demand.
@ACRrheum #ACR21 @rheumnow @bmsnews https://t.co/M4YegqJ5mt
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 8 months ago
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Links:
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 8 months ago
Prospective study of PsO screened @ derm clinics
🔹PsO➕>3 mo back pain starting <45yo➕no biologics➡️rheum ref, 100 pts seen➡️19 dx'ed as:
🔹14 axPsA, 68% met axSpA ASAS, 11/14 w/o pPsA
🔹5 pPsA w/o axial dz
https://t.co/azoks5CHCP
#ACR21 Abst#1796 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
